Inmunómica traslacional en neoplasias hematológicas
Hospital de Santa Maria
Lisboa, PortugalPublicaciones en colaboración con investigadores/as de Hospital de Santa Maria (4)
2020
-
International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)
Blood Cancer Journal, Vol. 10, Núm. 10
2016
-
Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under lendex: A longitudinal analysis
Blood, Vol. 127, Núm. 9, pp. 1151-1162
2015
-
Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up
British Journal of Haematology, Vol. 171, Núm. 3, pp. 344-354
2013
-
Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma
Journal of Clinical Oncology, Vol. 31, Núm. 2, pp. 247-255